The Dual Benefit of Tirzepatide in Patients with Type 2 Diabetes: Glycemic Control and Simultaneous Weight Loss.
Tirzepatide: The First Dual GLP-1/GIP Agonist
Mounjaro (tirzepatide) is the first medication to simultaneously activate GLP-1 and GIP receptors, two essential incretin hormones in glucose regulation and energy metabolism. This dual action provides tirzepatide with a unique advantage for patients with type 2 diabetes and obesity: it treats both conditions in parallel. The SURPASS (diabetes) and SURMOUNT (obesity) clinical trials have demonstrated this dual efficacy.
The SURPASS-1 to 4 trials, published in the New England Journal of Medicine and The Lancet, included over 9,000 diabetic patients. Results show a reduction in HbA1c of 1.87% to 2.07% depending on the dose (5 to 15 mg), combined with a weight loss of 7% to 13% of body weight. These results surpass those of all existing antidiabetic treatments, including semaglutide (Ozempic).
Mechanisms of Action on Glycemia
Tirzepatide improves glycemic control through several mechanisms: glucose-dependent stimulation of insulin secretion (insulin is released only when blood glucose is high, limiting the risk of hypoglycemia), suppression of glucagon secretion (a hyperglycemic hormone), slowing of gastric emptying (slower glucose absorption), and improved insulin sensitivity in peripheral tissues.
Advantages Over Other Antidiabetic Treatments
- Associated weight loss (unlike insulin, sulfonylureas, or glitazones, which cause weight gain)
- Low risk of hypoglycemia (glucose-dependent action)
- Single weekly administration (better adherence vs. daily injections)
- Documented cardiovascular and renal benefits
- Improvement in non-alcoholic steatohepatitis (NASH), frequently associated with diabetes
Recommendations from Scientific Societies
The French Society of Diabetology (SFD), the American Diabetes Association (ADA), and the EASD (European Association for the Study of Diabetes) recommend GLP-1 agonists as second-line treatment after metformin in patients with type 2 diabetes and obesity. Tirzepatide, thanks to its dual GLP-1/GIP action, represents a major therapeutic advance in this indication.
Track your progress with the MounjaGO app. MounjaGO is available for 5€ for life (one-time payment, zero subscription), as a Web app — no installation required, and uses 100% local storage (maximum privacy).
FAQ
What are the main recommendations for Mounjaro under GLP-1 treatment?
Key recommendations include regular medical follow-up, monitoring blood tests, adequate protein intake, and adapted physical activity. Consult your doctor for personalized advice for your situation.
Is tirzepatide (Mounjaro) effective for glycemic control?
The SURMOUNT and SURPASS clinical trials have demonstrated the efficacy of tirzepatide in this indication, with significant documented results. Your doctor will evaluate the relevance of the treatment for your individual profile.
What side effects should be monitored in connection with Mounjaro?
Side effects to monitor depend on your personal situation. The most common are gastrointestinal disturbances (nausea, diarrhea, constipation). Report any unusual symptoms to your doctor for evaluation.
How does the MounjaGO app help with Mounjaro?
MounjaGO offers comprehensive tracking of injections, weight, side effects, and generates PDF reports for your consultations. This structured tracking improves therapeutic adherence and communication with your doctor.